Show simple item record

dc.contributor.authorPrezioso, Carla
dc.contributor.authorCiotti, Marco
dc.contributor.authorBrazzini, Gabriele
dc.contributor.authorPiacentini, Francesca
dc.contributor.authorPasserini, Sara
dc.contributor.authorGrimaldi, Alfonso
dc.contributor.authorLandi, Doriana
dc.contributor.authorNicoletti, Carolina Gabri
dc.contributor.authorZingaropoli, Maria Antonella
dc.contributor.authorIannetta, Marco
dc.contributor.authorAltieri, Marta
dc.contributor.authorConte, Antonella
dc.contributor.authorLimongi, Dolores
dc.contributor.authorMarfia, Girolama Alessandra
dc.contributor.authorCiardi, Maria Rosa
dc.contributor.authorMastroianni, Claudio Maria
dc.contributor.authorPalamara, Anna Teresa
dc.contributor.authorMoens, Ugo
dc.contributor.authorPietropaolo, Valeria
dc.date.accessioned2022-05-11T07:10:08Z
dc.date.available2022-05-11T07:10:08Z
dc.date.issued2022-01-11
dc.description.abstractMarkers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC). The number of MS patients with viruria increased from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35–40%). Viremia first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.en_US
dc.identifier.citationPrezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini, Grimaldi, Landi, Nicoletti, Zingaropoli, Iannetta, Altieri, Conte A, Limongi, Marfia, Ciardi, Mastroianni, Palamara AT, Moens u, Pietropaolo V. Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. Journal of Clinical Medicine. 2022;11(2)en_US
dc.identifier.cristinIDFRIDAID 1978965
dc.identifier.doi10.3390/jcm11020347
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/10037/25065
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalJournal of Clinical Medicine
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.titleDiagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatmenten_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record